Multifunctional CAR T Cell Therapies for Antigen Escape
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T cell therapies face challenges such as high relapse rates due to antigen escape and tumor phenotype heterogeneity, limited efficacy in solid tumors, and suboptimal specificity, efficacy, and safety for cancers beyond leukemia. Additionally, existing bone marrow transplantation and hematopoietic stem cell transplantation methods are limited by severe safety and toxicity risks associated with high dose chemotherapy/irradiation conditioning regimens.
Innovation Solution
The development of multi-functional chimeric antigen receptor (CAR)-based compositions that include a cell expressing a CAR in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or redirect CAR cell-mediated immune responses by binding to specific antigenic determinants, thereby enhancing the targeting capabilities of CAR T cells and improving the safety profile of conditioning regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current CAR T cell therapies are used, then initial anti-tumor activity is achieved, but high relapse rates occur due to antigen escape and tumor phenotype heterogeneity
Solution Approach 1:
The patent employs multispecific CAR T cells that can simultaneously recognize and bind to multiple different tumor antigens (e.g., both CD19 and CD22). This multi-functionality allows the CAR T cells to target heterogeneous tumor populations and prevents antigen escape, thereby improving clinical response durability while maintaining adaptability to diverse tumor phenotypes
Solution Approach 2:
The patent utilizes inducible and switchable CAR systems that can dynamically adapt their target specificity. Through controllable expression of different CAR variants or antigen-binding specificities, the system can respond to changing tumor conditions and antigen expression patterns, enhancing both reliability and adaptability in treating relapsed diseases
2Productivity
If current CAR technologies are used, then treatment is provided for hematological cancers, but limited efficacy is achieved in solid tumors due to target heterogeneity
Solution Approach 1:
The patent designs multispecific CAR T cells capable of recognizing multiple tumor-associated antigens including both hematological cancer markers (CD19, CD22) and solid tumor markers. This universal targeting capability allows a single CAR T cell product to potentially treat multiple cancer types, improving productivity while expanding adaptability to different cancer phenotypes
Solution Approach 2:
The patent employs CAR T cells with tunable affinity and specificity parameters that can be optimized for different tumor types. By adjusting the antigen-binding domain characteristics and co-targeting strategies, the system achieves effective treatment across diverse cancers from leukemia to solid tumors
3Reliability
If bone marrow transplantation and hematopoietic stem cell transplantation are performed, then blood or immune diseases are corrected, but severe safety and toxicity risks occur due to high dose chemotherapy/irradiation conditioning regimens
Solution Approach 1:
The patent extracts and eliminates the need for high-dose chemotherapy and irradiation conditioning regimens by using CAR T cell therapy as a standalone treatment. This removes the harmful factors (severe toxicities including neutropenia, infections, organ damage) while preserving the disease correction capability through direct immunological targeting of the underlying conditions
4Productivity
If current CAR T cell generation methods are used, then CAR T cells are produced, but significant time is required for cell generation
Solution Approach 1:
The patent employs pre-engineered universal CAR T cell products that can be manufactured and stored before patient-specific needs arise. These off-the-shelf CAR T cells have pre-integrated antigen recognition capabilities and can be rapidly administered without requiring time-consuming patient-specific cell collection, processing, and manufacturing steps
Data Source
AI summary
Provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and their use in directing immune responses to target cells. The compositions have uses that include treating hyperproliferative disorders such as cancer. The provided methods generally include the use of a CAR cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or redirect CAR cell-mediated immune response in vitro and in vivo. In some embodiments, the CAR cell comprises a genetic modification to reduce or eliminate the expression of a targeted antigenic determinant